GLAXF GSK plc

NEUTRAL Impact: 3/10 6-K
Horizon immediate Filed Apr 10, 2026 Processed 2mo ago SEC 0001654954-26-003393
Notable filing: 6-K
Latest settled — T+20d ⚠ clustered
GLAXF ▼ -13.64% at T+20d
NEUTRAL call ✗ call lost -13.64% · α vs SPY -22.17% · entry $29.25 → $25.26
Next anchor: T+60d in 22d
Last close $26.63 (close Jun 12) · -8.96% from $29.25 entry
Entry anchored
Apr 10, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.98%
$29.25
settled 2mo ago
T+5d
+0.85%
call +0.85% · α -3.65%
$29.50
settled 8w ago
T+20d
-13.64%
call -13.64% · α -22.17%
$25.26
settled 5w ago
T+60d
call — · α —
in 22d

Price Chart

Loading chart...

Executive Summary

GSK plc repurchased 330,000 ordinary shares on April 9, 2026, at a volume-weighted average price of 2,139.38 GBp per share, as part of its ongoing buyback program. This transaction increases the company's treasury holdings to 257.8 million shares, representing 6.35% of total voting rights.

Actionable Insight

This is a routine share buyback within an announced program. While it slightly reduces shares outstanding which could support EPS, the transaction size is relatively small compared to the company's market cap. Monitor for continued buyback activity as an indicator of management's capital allocation priorities, but this single transaction has minimal immediate impact on valuation.

Key Facts

  • GSK repurchased 330,000 ordinary shares on April 9, 2026
  • Volume-weighted average price was 2,139.38 GBp per share
  • Treasury shares now total 257,787,615, representing 6.35% of voting rights
  • Purchase was executed through BNP Paribas SA as part of existing buyback program
  • Since February 17, 2026, company has purchased 17,896,521 ordinary shares

Financial Impact

Approximately $7.06 million spent on repurchase (330,000 shares × £21.3938)

shares outstandingtreasury stockearnings per share (potential future impact)

Risk Factors

  • Dilution of buyback impact if company issues new shares
  • Program could be suspended if financial conditions change

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-003393
Document: 0001654954-26-003393-index-headers.html0001654954-26-003393
Document: 0001654954-26-003393-index.html0001654954-26-003393
Document: 0001654954-26-003393.txt0001654954-26-003393
51 reports for GLAXF
Performance horizon
42% Hit rate 5 of 12 directional calls best @ T+5▲ +7.60%Apr 1, 2026
Filters
Rows
Reports for GLAXF — sortable, filterable
Type Now
Jun 10, 2026
4d ago
6-K
NEUTRAL ★ 1/10
$23.54 awaiting T+5awaiting T+5$26.63 (+13.13%)
Jun 9, 2026
5d ago
6-K
NEUTRAL ★ 1/10
$24.66 awaiting T+5awaiting T+5$26.63 (+7.99%)
Jun 9, 2026
5d ago
6-K
BULLISH ★ 7/10
$24.66 awaiting T+5awaiting T+5$26.63 (+7.99%)
Jun 1, 2026
13d ago
6-K
NEUTRAL ★ 1/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.63 (+9.81%)
Jun 1, 2026
13d ago
6-K
NEUTRAL ★ 2/10
$24.25 $24.66▲ +1.69%▲ +4.44%$26.63 (+9.81%)
May 28, 2026
17d ago
6-K
BULLISH ★ 7/10
$24.58 $24.66▲ +0.33%▲ +0.01%$26.63 (+8.34%)
May 27, 2026
18d ago
6-K
NEUTRAL ★ 1/10
$25.57 $23.94▼ −6.37%▼ −7.58%$26.63 (+4.15%)
May 26, 2026
19d ago
6-K
NEUTRAL ★ 1/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.63 (+4.43%)
May 26, 2026
19d ago
6-K
NEUTRAL ★ 2/10
$25.50 $24.25▼ −4.90%▼ −5.99%$26.63 (+4.43%)
May 22, 2026
23d ago
6-K
NEUTRAL ★ 2/10
$26.00 $24.25▼ −6.73%▼ −8.39%$26.63 (+2.42%)
Showing 10 of 51

US Market Status

Market Closed — Opens in 4h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access